Drugs / RESP302
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06663176 | Oct 2024 → Feb 2028 expected | bronchiectasis | Thirty Respiratory Limited | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RESP302 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06663176 ↗ |
| Route | Inhaled | “nebulised RESP302” NCT06663176 ↗ |